Anika Therapeutics, Inc. 4
4 · Anika Therapeutics, Inc. · Filed Feb 24, 2017
Insider Transaction Report
Form 4
Transactions
- Tax Payment
Common Stock
2017-02-22$49.20/sh−1,117$54,956→ 36,608 total - Exercise/Conversion
Common Stock
2017-02-22$6.99/sh+5,000$34,950→ 39,608 total - Sale
Common Stock
2017-02-22$49.02/sh−807$39,559→ 37,608 total - Exercise/Conversion
Stock Option (Right to buy)
2017-02-22−807→ 0 totalExercise: $6.99→ Common Stock (807 underlying) - Exercise/Conversion
Common Stock
2017-02-22$10.99/sh+5,000$54,950→ 37,725 total - Sale
Common Stock
2017-02-22$49.01/sh−2,000$98,020→ 34,608 total - Sale
Common Stock
2017-02-22$49.05/sh−1,193$58,517→ 38,415 total - Exercise/Conversion
Stock Appreciation Rights
2017-02-22−5,000→ 0 totalExercise: $10.99→ Common Stock (5,000 underlying) - Exercise/Conversion
Stock Option (Right to buy)
2017-02-22−4,193→ 20,000 totalExercise: $6.99→ Common Stock (4,193 underlying)
Footnotes (4)
- [F1]Exercise of stock appreciation rights ("SARS") granted on January 31, 2008, which vested in full on such date, and expiring on January 31, 2018.
- [F2]Reflects 1,117 shares of common stock utilized to cover the exercise price of the above listed SARs award by the Reporting Person on February 22, 2017.
- [F3]Exercise of 4,193 stock options granted on June 7, 2011 that are fully vested.
- [F4]Exercise of 807 stock options granted on June 7, 2011 that were fully vested.